Anika Therapeutics, Inc.
ANIK· Nasdaq
ANIKAnika Therapeutics, Inc.
Filed Mar 16, 2023 · 10-K · 75 days after period end · 0001171843-23-001729
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 |
|---|---|---|---|---|
| Revenue | — | $35.82M | $32.69M | $29.77M |
| Net Income | -$4.91M | -$5.79M | -$15.66M | $4.05M |
| EPS Diluted | — | — | -$1.10 | $0.28 |
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Mar 16, 2023 · 75 d after period end
